The diagnosis of pulmonary hypertension does not rely on a single test. Assessment begins with symptoms, clinical examination and noninvasive investigations, especially echocardiography, and continues by identifying the cause of increased pressure. When the hemodynamic abnormality needs to be confirmed and accurately classified, the reference test is right heart catheterization.
The current definition of pulmonary hypertension requires a mean pulmonary arterial pressure greater than 20 mmHg at rest, measured invasively. An estimated pressure value obtained by echocardiography alone is therefore not equivalent to a diagnosis.
In practice, the diagnostic pathway seeks to answer three questions:
This distinction is essential because pulmonary hypertension is not a single disease. It may be caused by small pulmonary vessel disease, left heart disorders, respiratory diseases or hypoxia, chronic thromboembolic obstructions or more complex mechanisms.
The diagnostic process often begins because of unexplained shortness of breath on exertion, fatigue, reduced exercise capacity, dizziness or syncope. At other times, suspicion arises from an echocardiogram performed for another reason or from screening individuals with conditions that increase the risk of certain forms of pulmonary hypertension.
The medical history explores cardiac and lung diseases, previous thromboembolic events, connective tissue diseases, congenital heart defects, portal hypertension, HIV infection, family history and possible exposure to medications or substances associated with pulmonary arterial hypertension. Examination looks for signs of right heart overload, congestion, hypoxemia and clues to the underlying disease.
Initial investigations may include electrocardiography, chest radiography, oxygen saturation measurement and blood tests. BNP or NT-proBNP may rise when the heart, including the right ventricle, is under strain, but they do not identify the cause on their own and are not specific to pulmonary hypertension.
These investigations also help identify alternative diagnoses. This is important because dyspnea and fatigue are very common symptoms: the goal is not to force every presentation into a pulmonary hypertension diagnosis, but to identify those requiring further investigations.
Transthoracic echocardiography is the central noninvasive examination during initial detection. It assesses tricuspid regurgitation velocity, right ventricular size and function, the right atrium, interventricular septum, inferior vena cava and other parameters that may suggest increased pressure loading within the pulmonary circulation.
However, it is not interpreted as a simple "yes/no" test. Guidelines combine tricuspid regurgitation velocity with other signs to assign a low, intermediate or high echocardiographic probability. The examination may also reveal a possible cardiac cause, such as left ventricular dysfunction or valvular disease.
An elevated PAPs or sPAP on the report is therefore one element of the overall picture, not confirmation of disease. Systolic pressure is estimated indirectly and may be overestimated or underestimated. The hemodynamic threshold greater than 20 mmHg instead refers to mean pulmonary arterial pressure measured by catheterization.
When echocardiography, symptoms and clinical context indicate a significant probability, the next step is to understand why pressure might be elevated and whether the condition is one for which an invasive diagnosis would have therapeutic implications.
Assessment of the causes must be multimodal. Pulmonary function tests, including diffusing capacity for carbon monoxide (DLCO), help identify obstructive or restrictive diseases and gas-exchange abnormalities. Depending on the clinical presentation, arterial blood gas analysis, overnight oximetry or a sleep study may be used when hypoventilation or sleep-disordered breathing is suspected.
Chest CT may reveal emphysema, interstitial lung disease and other pulmonary parenchymal findings, as well as indirect signs of pulmonary hypertension. CT pulmonary angiography also plays an important role when chronic thromboembolic disease is suspected.
The ventilation/perfusion (V/Q) scan has a specific role: it is recommended when pulmonary hypertension is suspected or newly diagnosed to detect abnormalities compatible with chronic thromboembolic disease. In the absence of significant pulmonary parenchymal disease, normal perfusion makes CTEPH very unlikely.
Recognizing chronic thromboembolic pulmonary hypertension is particularly important because specific and potentially highly effective treatment strategies are available.
Blood tests are selected according to the medical history and clinical suspicion. They may include renal and liver function tests, a complete blood count, iron studies, thyroid function, HIV testing, autoantibodies if a connective tissue disease is possible and other targeted investigations. Abdominal imaging may be useful when findings suggest liver disease or portal hypertension.
Not everyone needs every test. The diagnostic pathway is adapted to the probability of different causes, avoiding both missed investigations and indiscriminate batteries of tests.
The procedure known as Right heart catheterization is the reference standard for hemodynamically defining and classifying pulmonary hypertension. A thin catheter is advanced through the venous system into the right heart chambers and pulmonary artery, allowing direct measurement of pressures and cardiac output. Key measurements include right atrial pressure, pulmonary arterial pressure, mean pulmonary arterial pressure (mPAP), pulmonary artery wedge pressure (PAWP) and cardiac output; pulmonary vascular resistance (PVR) is calculated from these measurements.
An mPAP greater than 20 mmHg defines pulmonary hypertension. However, PAWP and PVR are also needed to understand its mechanism. A pre-capillary form is characterized by mPAP greater than 20 mmHg, PAWP not exceeding 15 mmHg and PVR greater than 2 Wood units. When PAWP exceeds 15 mmHg, the condition is instead referred to as post-capillary pulmonary hypertension, typically linked to increased left heart pressures; isolated forms are further distinguished from those with an associated pre-capillary component.
This classification is not an academic detail: it prevents conditions with different pathophysiology and treatment from being managed identically.
Catheterization is not performed automatically for every mildly elevated pressure estimate on echocardiography. It is particularly important when pulmonary arterial hypertension or CTEPH is suspected, or when precise hemodynamic measurements may alter prognosis and treatment. In some people with mild pulmonary hypertension and clearly predominant left heart or lung disease, invasive testing may not provide useful additional information.
When indicated, it should be performed and interpreted using rigorous methods, preferably at centers experienced in pulmonary vascular diseases.
Assessment should be accelerated if there is a high probability of severe pulmonary vascular disease, particularly when syncope or presyncope occurs with mild exertion, functional capacity deteriorates rapidly, hypotension develops or signs of right ventricular failure appear. Recommendations from the 7th World Symposium on Pulmonary Hypertension call for prompt referral to a dedicated center in these circumstances, without waiting for every diagnostic step to be completed sequentially.
A specialist center is particularly important when PAH or CTEPH is suspected, in complex forms with several possible mechanisms, and when treatment decisions depend on precise hemodynamic and radiologic characterization.
Even after pulmonary hypertension is demonstrated, the diagnostic process is incomplete until the predominant clinical group is identified. For example, pulmonary hypertension due to left heart disease and pulmonary hypertension associated with lung diseases require a different approach from PAH.
Once the disease type has been established, exercise capacity, right ventricular function, biomarkers and other indicators are also assessed to determine severity, risk and follow-up. Tests such as the 6-minute walk test therefore play an important role in functional and prognostic assessment but do not replace hemodynamic demonstration of disease.
Which test confirms pulmonary hypertension?
When hemodynamic confirmation is indicated, right heart catheterization is the reference test. It measures pressures directly and allows pulmonary vascular resistance to be calculated.
Can echocardiography alone diagnose pulmonary hypertension?
No. It is essential for estimating probability and assessing the heart, but cannot confirm the hemodynamic diagnosis on its own.
Which pressure defines pulmonary hypertension?
The current definition requires a mean pulmonary arterial pressure greater than 20 mmHg at rest, measured by right heart catheterization. PAWP and PVR then allow the hemodynamic type to be classified.
Why is ventilation/perfusion scintigraphy performed?
It is used to detect perfusion defects that may indicate chronic thromboembolic disease. This is an important step because CTEPH is a cause of pulmonary hypertension for which specific treatments are available.
Is right heart catheterization always necessary?
No. It is essential when it may alter diagnosis, classification or treatment, especially if PAH or CTEPH is suspected. In some mild forms clearly due to left heart or lung disease, it may not be indicated if it would have no therapeutic consequences.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.